RecruitingPhase 4NCT04690322
POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
Studying Severe hemophilia A
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Texas Southwestern Medical Center
- Principal Investigator
- Jessica Garcia, MDUniversity of Texas Southwestern Medical Center
- Intervention
- Eloctate(drug)
- Enrollment
- 28 target
- Eligibility
- 17 years · All sexes
- Timeline
- 2021 – 2027
Study locations (1)
- The University of Texas Southwestern Medical Center, Dallas, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04690322 on ClinicalTrials.govOther trials for Severe hemophilia A
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNANCT06816953Cartilage Biomarkers and HEAD-US Score in Severe Hemophilia A Patients Receiving FVIII ProphylaxisChulalongkorn University
- RECRUITINGPHASE3NCT06142552Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinJiangsu Gensciences lnc.
- ACTIVE NOT RECRUITINGPHASE3NCT06224907Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia ABioMarin Pharmaceutical
- RECRUITINGNCT05981274A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)Tri-Service General Hospital
- ENROLLING BY INVITATIONNCT05768386A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)BioMarin Pharmaceutical